<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942407</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00068545</org_study_id>
    <nct_id>NCT02942407</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation</brief_title>
  <acronym>RENAL-AF</acronym>
  <official_title>RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christopher Granger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, open-label, blinded end-point evaluation trial. The
      patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and
      end-stage renal disease (ESRD) .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter study in adult patients with AF and ESRD who are on hemodialysis and
      who have stroke risk factors making them candidates for oral anticoagulation. Patients will
      be randomized to apixaban versus warfarin, and will be treated for up to 15 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time (measured in days) from randomization to the onset of first major bleeding/clinically relevant non-major bleeding event, as described by International Society of Thrombosis and Haemostasis (ISTH)</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>stroke or systemic embolism</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>15 months</time_frame>
    <description>all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adherence to treatment with apixaban or with warfarin, measured by pill count for patients randomized to apixaban, and by time in therapeutic range (TTR) for warfarin</measure>
    <time_frame>15 months</time_frame>
    <description>including discontinuation for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apixaban plasma concentration.</measure>
    <time_frame>Baseline: Day 3, 4, or 5; Day 28</time_frame>
    <description>Pharmacokinetics; only in the apixaban treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma apixaban concentration, Cmax</measure>
    <time_frame>Baseline: Day 3, 4, or 5; Day 28</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma apixaban concentration, Cmin</measure>
    <time_frame>Baseline: Day 3, 4, or 5; Day 28</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma apixaban concentration, area under the curve (AUC)</measure>
    <time_frame>Baseline: Day 3, 4, or 5; Day 28</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apixaban pharmacodynamics, chromogenic factor Xa assay</measure>
    <time_frame>Baseline: Day 3, 4, or 5; Day 28</time_frame>
    <description>Pharmacodynamics</description>
  </secondary_outcome>
  <other_outcome>
    <measure>baseline biomarkers to assess for prediction of clinical outcomes such as bleeding. Biomarkers to be assessed are Growth/differentiation factor 15(GDF-15), high sensitivity troponin T (hs-trop T), B-type natriuretic peptide (NT-proBNP).</measure>
    <time_frame>Baseline</time_frame>
    <description>Biomarker</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">762</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apixaban 5 mg twice daily (apixaban 2.5 mg twice daily for selected patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>warfarin daily dose adjusted to target International Normalized Ration(INR) of 2-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apixaban</intervention_name>
    <description>oral anticoagulant</description>
    <arm_group_label>apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>oral anticoagulant</description>
    <arm_group_label>warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
    <other_name>Jantoven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, age at least 18 years, or the local age of consent, whichever is
             greater.

          -  Patients with AF defined as AF on ECG at enrollment or two or more reports of AF from
             separate monitoring events at least 2 weeks apart (report of ECG, Holter monitor,
             event monitor or implantable loop recorder).

          -  CHA2DS2-VASc score of ≥ 2.

          -  End-stage renal disease treated with hemodialysis for ≥ 3 months.

          -  Considered by the treating physician(s) to be candidate for oral anticoagulation.

          -  If of childbearing potential, be willing to avoid pregnancy during the study.

        Exclusion Criteria:

          -  Not considered by the treating physician(s) to be candidates for oral anticoagulation
             (for example, hemoglobin &lt; 8.5g/dL, history of intracranial hemorrhage, active
             bleeding, recent gastrointestinal bleed or retroperitoneal bleed, severe hepatic
             impairment, or anaphylactic reaction to apixaban)

          -  Moderate or severe mitral stenosis

          -  Conditions other than AF that require anticoagulation such as mechanical prosthetic
             valve, deep venous thrombosis, or pulmonary embolism

          -  Need for aspirin at a dose &gt; 81 mg a day or need for P2Y12 antagonist therapy (for
             example clopidogrel, prasugrel, or ticagrelor)

          -  Life expectancy &lt; 3 months

          -  Anticipated kidney transplant within the next 3 months

          -  Prisoners or others who are involuntarily incarcerated or detained

          -  Pregnant, breastfeeding, or considering pregnancy.

          -  Participation in a clinical trial of an experimental treatment within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Granger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glenn Chertow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pat Dignacco, BSMT</last_name>
    <phone>919-668-8482</phone>
    <email>pat.dignacco@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Genesis Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Berrios</last_name>
      <email>Eric.Berrios@fmc-na.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boise Kidney and Hypertension Institute</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Berrios</last_name>
      <email>Eric.Berrios@fmc-na.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Shore Nephrology</name>
      <address>
        <city>Plymouth</city>
        <state>Massachusetts</state>
        <zip>02360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Berrios</last_name>
      <email>Eric.Berrios@fmc-na.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paragon Health Neprhology Centre</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Berrios</last_name>
      <email>Eric.Berrios@fmc-na.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nephrology &amp; Hypertension Associates</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Berrios</last_name>
      <email>Eric.Berrios@fmc-na.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metro Hypertension &amp; Kidney Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Berrios</last_name>
      <email>Eric.Berrios@fmc-na.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Durham Nephrology Associates</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Berrios</last_name>
      <email>Eric.Berrios@fmc-na.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research Ctr</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Berrios</last_name>
      <email>Eric.Berrios@fmc-na.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Knoxville Kidney Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Berrios</last_name>
      <email>Eric.Berrios@fmc-na.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010 Jun;77(12):1098-106. doi: 10.1038/ki.2009.477. Epub 2010 Jan 6.</citation>
    <PMID>20054291</PMID>
  </reference>
  <reference>
    <citation>Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012 Aug 16;367(7):625-35. doi: 10.1056/NEJMoa1105594. Erratum in: N Engl J Med. 2012 Dec 6;367(23):2262.</citation>
    <PMID>22894575</PMID>
  </reference>
  <reference>
    <citation>Nigwekar SU, Bhan I, Turchin A, Skentzos SC, Hajhosseiny R, Steele D, Nazarian RM, Wenger J, Parikh S, Karumanchi A, Thadhani R. Statin use and calcific uremic arteriolopathy: a matched case-control study. Am J Nephrol. 2013;37(4):325-32. doi: 10.1159/000348806. Epub 2013 Mar 21.</citation>
    <PMID>23548843</PMID>
  </reference>
  <reference>
    <citation>Yang F, Chou D, Schweitzer P, Hanon S. Warfarin in haemodialysis patients with atrial fibrillation: what benefit? Europace. 2010 Dec;12(12):1666-72. doi: 10.1093/europace/euq387. Epub 2010 Nov 2. Review.</citation>
    <PMID>21045011</PMID>
  </reference>
  <reference>
    <citation>Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009 Oct;20(10):2223-33. doi: 10.1681/ASN.2009030319. Epub 2009 Aug 27.</citation>
    <PMID>19713308</PMID>
  </reference>
  <reference>
    <citation>Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014 Mar 18;129(11):1196-203. doi: 10.1161/CIRCULATIONAHA.113.004777. Epub 2014 Jan 22.</citation>
    <PMID>24452752</PMID>
  </reference>
  <reference>
    <citation>Granger CB, Chertow GM. A pint of sweat will save a gallon of blood: a call for randomized trials of anticoagulation in end-stage renal disease. Circulation. 2014 Mar 18;129(11):1190-2. doi: 10.1161/CIRCULATIONAHA.113.007549. Epub 2014 Jan 22.</citation>
    <PMID>24452751</PMID>
  </reference>
  <reference>
    <citation>Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015 Mar 17;131(11):972-9. doi: 10.1161/CIRCULATIONAHA.114.014113. Epub 2015 Jan 16.</citation>
    <PMID>25595139</PMID>
  </reference>
  <reference>
    <citation>Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011 Nov;6(11):2599-604. doi: 10.2215/CJN.02400311. Epub 2011 Sep 8.</citation>
    <PMID>21903982</PMID>
  </reference>
  <reference>
    <citation>Reinecke H, Brand E, Mesters R, Schäbitz WR, Fisher M, Pavenstädt H, Breithardt G. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol. 2009 Apr;20(4):705-11. doi: 10.1681/ASN.2007111207. Epub 2008 Dec 17. Review.</citation>
    <PMID>19092127</PMID>
  </reference>
  <reference>
    <citation>Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857-67.</citation>
    <PMID>17577005</PMID>
  </reference>
  <reference>
    <citation>Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011 Nov;6(11):2662-8. doi: 10.2215/CJN.04550511. Epub 2011 Sep 29.</citation>
    <PMID>21959598</PMID>
  </reference>
  <reference>
    <citation>Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012 Nov;33(22):2821-30. doi: 10.1093/eurheartj/ehs274. Epub 2012 Aug 29.</citation>
    <PMID>22933567</PMID>
  </reference>
  <reference>
    <citation>Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007 Sep;50(3):433-40. Review.</citation>
    <PMID>17720522</PMID>
  </reference>
  <reference>
    <citation>Wu JR, DeWalt DA, Baker DW, Schillinger D, Ruo B, Bibbins-Domingo K, Macabasco-O'Connell A, Holmes GM, Broucksou KA, Erman B, Hawk V, Cene CW, Jones CD, Pignone M. A single-item self-report medication adherence question predicts hospitalisation and death in patients with heart failure. J Clin Nurs. 2014 Sep;23(17-18):2554-64. doi: 10.1111/jocn.12471. Epub 2013 Dec 20.</citation>
    <PMID>24355060</PMID>
  </reference>
  <reference>
    <citation>Gonzalez JS, Schneider HE, Wexler DJ, Psaros C, Delahanty LM, Cagliero E, Safren SA. Validity of medication adherence self-reports in adults with type 2 diabetes. Diabetes Care. 2013 Apr;36(4):831-7. doi: 10.2337/dc12-0410. Epub 2012 Nov 30.</citation>
    <PMID>23204245</PMID>
  </reference>
  <reference>
    <citation>Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014 Jul 21;35(28):1864-72. doi: 10.1093/eurheartj/ehu046. Epub 2014 Feb 20.</citation>
    <PMID>24561548</PMID>
  </reference>
  <reference>
    <citation>Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011 Oct;32(19):2387-94. doi: 10.1093/eurheartj/ehr342. Epub 2011 Aug 28.</citation>
    <PMID>21873708</PMID>
  </reference>
  <reference>
    <citation>Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990 Dec;9(12):1447-54.</citation>
    <PMID>2281232</PMID>
  </reference>
  <reference>
    <citation>Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432. Epub 2011 Feb 10.</citation>
    <PMID>21309657</PMID>
  </reference>
  <reference>
    <citation>Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.</citation>
    <PMID>21870978</PMID>
  </reference>
  <reference>
    <citation>Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011 Sep;80(6):572-86. doi: 10.1038/ki.2011.223. Epub 2011 Jul 13.</citation>
    <PMID>21750584</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Christopher Granger</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Renal dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

